全文获取类型
收费全文 | 419379篇 |
免费 | 32962篇 |
国内免费 | 13694篇 |
专业分类
耳鼻咽喉 | 3172篇 |
儿科学 | 6185篇 |
妇产科学 | 5693篇 |
基础医学 | 61744篇 |
口腔科学 | 7673篇 |
临床医学 | 31348篇 |
内科学 | 66509篇 |
皮肤病学 | 5477篇 |
神经病学 | 31390篇 |
特种医学 | 11368篇 |
外国民族医学 | 65篇 |
外科学 | 30616篇 |
综合类 | 59655篇 |
现状与发展 | 55篇 |
一般理论 | 14篇 |
预防医学 | 27037篇 |
眼科学 | 4886篇 |
药学 | 58935篇 |
100篇 | |
中国医学 | 21236篇 |
肿瘤学 | 32877篇 |
出版年
2024年 | 790篇 |
2023年 | 6001篇 |
2022年 | 12675篇 |
2021年 | 18962篇 |
2020年 | 14591篇 |
2019年 | 13305篇 |
2018年 | 13201篇 |
2017年 | 14079篇 |
2016年 | 14545篇 |
2015年 | 15476篇 |
2014年 | 21661篇 |
2013年 | 27131篇 |
2012年 | 23392篇 |
2011年 | 27153篇 |
2010年 | 20421篇 |
2009年 | 20665篇 |
2008年 | 21870篇 |
2007年 | 21802篇 |
2006年 | 19915篇 |
2005年 | 18100篇 |
2004年 | 15142篇 |
2003年 | 13422篇 |
2002年 | 10597篇 |
2001年 | 9230篇 |
2000年 | 7769篇 |
1999年 | 6803篇 |
1998年 | 5829篇 |
1997年 | 5621篇 |
1996年 | 5078篇 |
1995年 | 4387篇 |
1994年 | 4139篇 |
1993年 | 3457篇 |
1992年 | 3047篇 |
1991年 | 2873篇 |
1990年 | 2417篇 |
1989年 | 2007篇 |
1988年 | 1897篇 |
1987年 | 1661篇 |
1986年 | 1529篇 |
1985年 | 2300篇 |
1984年 | 1999篇 |
1983年 | 1424篇 |
1982年 | 1513篇 |
1981年 | 1233篇 |
1980年 | 1114篇 |
1979年 | 866篇 |
1978年 | 588篇 |
1977年 | 489篇 |
1976年 | 467篇 |
1975年 | 334篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
32.
33.
《Transfusion and apheresis science》2022,61(4):103488
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection. 相似文献
34.
35.
《Journal of infection and chemotherapy》2022,28(2):352-355
IntroductionMonoclonal antibody therapy has been reported to be highly effective for preventing hospitalisation and severe cases in patients with Coronavirus Disease 2019 (COVID-19). However, since the drug is not readily available, it is important to rapidly and appropriately identify high-risk patients who can benefit most from therapy. Therefore, we designed a risk scoring system to identify at-risk COVID-19 patients in our region during the largest surge of COVID-19, from July to September 2021.MethodsAccording to the risk scores, confirmed COVID-19 patients were introduced to receive REGN-CoV-2 to our hospital by regional health centre from 18th August (Term 3). The primary outcome was the comparison of the number of hospitalisation and severe condition with other periods, the 4th wave (Term 1) and the early part of the 5th wave (Term 2) in Japan.ResultsDuring Term 3, 115 patients were stratified with the scoring system and administered REGN-COV-2. The number of hospitalisation vs severe cases were 60 (5.2%) vs 14 (1.2%), 8 (1.5%) vs 3 (0.6%) and 21 (1.2%) vs 2 (0.1%), in term 1, 2 and 3, respectively. Among those aged <60 years, compared with term 1, the relative risk of hospitalisation and severe condition were 0.25 (95% CI: 0.12–0.53) and 0.10 (95% CI: 0.01–0.80), respectively, in term 3. Drug adverse events were fever (3: 2.6%), headache (1: 0.9%) and neck rash (1: 0.9%), all events were resolved within 24 h wth no serious adverse event.ConclusionsThe administration of monoclonal antibody therapy using a risk scoring system significantly reduced the number of hospitalisation and disease severity of COVID-19 without any serious adverse events and avoided regional medical collapse. 相似文献
36.
《Vaccine》2022,40(32):4440-4452
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prevention of SARS-CoV-2 transmission has become a global priority. Previously, we showed that a protein subunit vaccine that was developed based on the fusion of the SARS-CoV-2 receptor-binding domain (RBD) to the Fc portion of human IgG1 (RBD-Fc), produced in Nicotiana benthamiana, and adjuvanted with alum, namely, Baiya SARS-CoV-2 Vax 1, induced potent immunological responses in both mice and cynomolgus monkeys. Hence, this study evaluated the protective efficacy, safety, and toxicity of Baiya SARS-CoV-2 Vax 1 in K18-hACE2 mice, monkeys and Wistar rats. Two doses of vaccine were administered three weeks apart on Days 0 and 21. The administration of the vaccine to K18-hACE2 mice reduced viral loads in the lungs and brains of the vaccinated animals and protected the mice against challenge with SARS-CoV-2. In monkeys, the results of safety pharmacology tests, general clinical observations, and a core battery of studies of three vital systems, namely, the central nervous, cardiovascular, and respiratory systems, did not reveal any safety concerns. The toxicology study of the vaccine in rats showed no vaccine-related pathological changes, and all the animals remained healthy under the conditions of this study. Furthermore, the vaccine did not cause any abnormal toxicity in rats and was clinically tolerated even at the highest tested concentration. In addition, general health status, body temperature, local toxicity at the administration site, hematology, and blood chemistry parameters were also monitored. Overall, this work presents the results of the first systematic study of the safety profile of a plant-derived vaccine, Baiya SARS-CoV-2 Vax 1; this approach can be considered a viable strategy for the development of vaccines against COVID-19. 相似文献
37.
《Vaccine》2022,40(16):2370-2378
Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Since PRRSV and Mhp co-infections are very common, an efficient dual vaccine against these pathogens is required for the global swine industry. Compared with traditional vaccines, multi-epitope vaccines have several advantages, they are comparatively easy to produce and construct, are chemically stable, and do not have an infectious potential. In this study, to develop a safe and effective vaccine, B cell and T cell epitopes of PRRSV-GP5, PRRSV-M, Mhp-P46, and Mhp-P65 protein had been screened to construct a recombinant epitope protein rEP-PM that has good hydrophilicity, strong antigenicity, and high surface accessibility, and each epitope is independent and complete. After immunization in mice, rEP-PM could induce the production of high levels of antibodies, and it had good immunoreactivity with anti-rEP-PM, anti-PRRSV, and anti-Mhp antibodies. The anti-rEP-PM antibody specifically recognizes proteins from PRRSV and Mhp. Moreover, rEP-PM induced a Th1-dominant cellular immune response in mice. Our results showed that the rEP-PM protein could be a potential candidate for the development of a safe and effective multi-epitope peptide combined vaccine to control PRRSV and Mhp infections. 相似文献
38.
39.
目的 探讨溶质载体蛋白(SLC)及其受体趋化因子受体7(CCR7)与I期非小细胞肺癌(NSCLC)淋巴结微转移的相关性。方法 选取2019年1月~2020年3月于我院就诊的I期NSCLC患者127例为研究对象,按照淋巴结微转移情况分为对照组92例和转移组35例,所有患者入院后均通过根治术切除病灶,通过免疫组化方式检测病灶中SLC7A11及CCR7含量,并收集患者临床资料、实验室检查资料及影像学检查资料。通过Logistic回归分析评价SLC7A11及CCR7与淋巴结微转移之间的关系。最后通过建立ROC曲线分析两者及其联合检测对NSCLC患者微淋巴结转移的预测价值。结果 两组患者SLC7A11及CCR7表达水平存在显著差异(P<0.05)。转移组患者病灶直径、支气管受累及TLG显著高于对照组(P<0.05)。病灶直径(OR=49.254,95%CI=11.062~507.604)是影响NSCLC淋巴结微转移的独立危险因素(P<0.05)。SLC7A11(OR=8.622)及CCR7(OR=8.709)表达水平是影响NSCLC淋巴结微转移的独立因素(P<0.05)。SLC7A11、CCR7及联合诊断对NSCLC淋巴结微转移具有较好的检测价值(均P<0.05)。联合检测特异度显著高于 SLC7A11及CCR7单独检测(2=7.292,15.125;均P<0.01)。结论 SLC家族的中SLC7A11及其受体CCR7与NSCLC患者微淋巴结转移显著相关。 相似文献
40.